Organon & Co. (NYSE:OGN) is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co. in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies. The company’s offerings extend to emerging areas such as endometriosis and osteoporosis, underscoring its commitment to advancing care for women throughout various life stages. This specialized focus leverages decades of research and clinical experience inherited from its predecessor organization.
Organon’s biosimilars division develops and markets lower-cost versions of complex biologic therapies. Its pipeline includes multiple biosimilar candidates designed to increase patient access to treatments for autoimmune disorders and other serious conditions. By combining in-house development capabilities with strategic partnerships, Organon aims to build a sustainable biosimilars business that complements its branded product lines.
With operations spanning more than 140 countries, Organon serves diverse markets across North America, Europe, Latin America, Asia and emerging regions. The company is led by President and Chief Executive Officer Kevin Ali, who oversees global strategy and operations. Organon’s corporate vision emphasizes innovation, patient-centricity and the responsible stewardship of its legacy products to drive long-term growth and healthcare advancement.
